{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:6083",
      "entity_text" : "adenosine monophosphate",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0115" ],
      "Species" : [ "taxonomy:9986" ]
    }
  },
  "verbose_text" : "37 Levosimendan is a new calcium sensitiser that enhances myocardial contractility without increasing the intracellular calcium load or intracellular cyclic adenosine monophosphate level; at the therapeutic dose, levosimendan does not cause ventricular arrhythmias and improves myocardial injury in sepsis due to mitochondrial damage, apoptosis inducing factor, calcium overload, and other factors, leading to decreased myocardial contractility.",
  "reading_complete" : "2020-08-09T19:37:50Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-09T19:36:27Z",
  "trigger" : "level",
  "evidence" : [ "adenosine monophosphate level" ],
  "pmc_id" : "6567749",
  "score" : 0
}